Trials / Completed
CompletedNCT03023319
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Nagla Abdel Karim · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Mesothelioma
- Bladder Cancer
- Ovarian Cancer
- Peritoneal Cancer
- Thymoma
- Thymus Cancer
- Uterine Cervical Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bosutinib | 100mg daily for 4 cycles (21 days per cycle) |
| DRUG | Pemetrexed | 500 mg/m2 every 21 days for 4 cycles |
Timeline
- Start date
- 2019-12-10
- Primary completion
- 2022-05-10
- Completion
- 2022-05-10
- First posted
- 2017-01-18
- Last updated
- 2022-06-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03023319. Inclusion in this directory is not an endorsement.